Published in Cell on November 27, 1992
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev (2000) 9.36
Modes of p53 regulation. Cell (2009) 9.31
DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev (1998) 7.78
DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev (1997) 5.76
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev (2000) 5.72
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. Mol Cell Biol (1999) 5.10
Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol (1996) 5.01
p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol (1999) 4.88
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J (1999) 4.68
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
Molecular chaperones as HSF1-specific transcriptional repressors. Genes Dev (1998) 3.72
Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A (1994) 3.36
Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol (1994) 3.30
Regulation of p53 function and stability by phosphorylation. Mol Cell Biol (1999) 3.24
Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell (2007) 3.20
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol (1994) 3.05
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.87
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell (2008) 2.67
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev (1998) 2.40
Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev (1997) 2.37
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci U S A (1995) 2.27
p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J (1996) 2.25
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J (1993) 2.21
p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J (1993) 2.16
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A (1998) 2.11
Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol (1996) 1.99
Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol (2000) 1.93
T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. Microbiol Mol Biol Rev (2002) 1.92
Role of cysteine residues in regulation of p53 function. Mol Cell Biol (1995) 1.91
Activation and activities of the p53 tumour suppressor protein. Br J Cancer (2001) 1.90
Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J (1997) 1.85
Characterization of the cooperative function of inhibitory sequences in Ets-1. Mol Cell Biol (1996) 1.85
Having it both ways: transcription factors that bind DNA and RNA. Nucleic Acids Res (2002) 1.84
DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell (2006) 1.78
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J (1993) 1.77
Methylation-acetylation interplay activates p53 in response to DNA damage. Mol Cell Biol (2007) 1.75
The NS1 polypeptide of the murine parvovirus minute virus of mice binds to DNA sequences containing the motif [ACCA]2-3. J Virol (1995) 1.72
Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J (1997) 1.70
Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol (1998) 1.69
Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol (1995) 1.63
At the crossroads of inflammation and tumorigenesis. J Exp Med (1999) 1.61
p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol (2002) 1.59
The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J (1995) 1.58
p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J (1994) 1.57
Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem (2003) 1.56
PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A (2000) 1.55
Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol (2001) 1.54
Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol (1994) 1.54
The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A (1995) 1.52
p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle (2010) 1.51
A temperature-sensitive mutant of human p53. EMBO J (1994) 1.51
Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM. Proc Natl Acad Sci U S A (1999) 1.50
Conformation-dependent phosphorylation of p53. Proc Natl Acad Sci U S A (1997) 1.49
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
Role of p53 serine 46 in p53 target gene regulation. PLoS One (2011) 1.48
Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol (2003) 1.48
The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol (2005) 1.45
p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol (1999) 1.44
CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One (2009) 1.43
Interaction of p53 with the human Rad51 protein. Nucleic Acids Res (1997) 1.43
A single-molecule characterization of p53 search on DNA. Proc Natl Acad Sci U S A (2010) 1.43
Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol (2002) 1.43
Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J (2001) 1.42
ei24, a p53 response gene involved in growth suppression and apoptosis. Mol Cell Biol (2000) 1.42
Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol (1993) 1.42
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol (1993) 1.42
Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol (1994) 1.39
Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc Natl Acad Sci U S A (1998) 1.39
Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death. Proc Natl Acad Sci U S A (2000) 1.39
Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res (1995) 1.37
p53 Isoforms: An Intracellular Microprocessor? Genes Cancer (2011) 1.37
Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J Virol (1997) 1.37
Participation of the human p53 3'UTR in translational repression and activation following gamma-irradiation. EMBO J (1997) 1.37
Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia (2000) 1.36
The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol (1997) 1.34
Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J (1996) 1.34
Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol Cell Biol (1999) 1.34
Characterization of quail Pax-6 (Pax-QNR) proteins expressed in the neuroretina. Mol Cell Biol (1993) 1.33
Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response. Proc Natl Acad Sci U S A (1997) 1.33
Erythroid Krüppel-like factor (EKLF) contains a multifunctional transcriptional activation domain important for inter- and intramolecular interactions. EMBO J (1996) 1.33
Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A (1996) 1.31
Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev (1998) 1.31
Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis (2013) 1.31
p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol (1997) 1.31
Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol (1999) 1.30
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J Virol (1998) 1.28
The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med (2011) 1.28
p53 induction is associated with neuronal damage in the central nervous system. Proc Natl Acad Sci U S A (1994) 1.27
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J (2006) 1.26
Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. Proc Natl Acad Sci U S A (1994) 1.25
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J (1990) 6.34
Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell (1985) 5.88
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature (1980) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 3.15
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. Nucleic Acids Res (1989) 3.15
Two pathways for base excision repair in mammalian cells. J Biol Chem (1996) 3.01
Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J (1999) 3.00
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
Requirement for the replication protein SSB in human DNA excision repair. Nature (1991) 2.80
Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature (1988) 2.77
Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity. J Biol Chem (1981) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. Virology (1978) 2.49
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 2.42
p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41
Structure and function of SV40 large-T antigen. Philos Trans R Soc Lond B Biol Sci (1987) 2.37
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
DbpA: a DEAD box protein specifically activated by 23s rRNA. EMBO J (1993) 2.04
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Nuclear protein p68 is an RNA-dependent ATPase. EMBO J (1989) 1.98
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res (1992) 1.91
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem (1995) 1.82
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays (1995) 1.75
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol (1995) 1.75
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73
Cancer. A death in the life of p53. Nature (1993) 1.70
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Mol Cell Biol (1991) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. EMBO J (1992) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene (1992) 1.60
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53
Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A (2000) 1.52
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene (1995) 1.51
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
Ku selectively transfers between DNA molecules with homologous ends. J Biol Chem (1997) 1.46
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene (1997) 1.46
The p53 response to ionising radiation in adult and developing murine tissues. Oncogene (1996) 1.46
APC expression in normal human tissues. J Pathol (1997) 1.44
The complex between simian virus 40 T antigen and a specific host protein. Proc R Soc Lond B Biol Sci (1980) 1.41
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene (1991) 1.40
Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell (1992) 1.39
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
Identification of novel mdm2 binding peptides by phage display. Oncogene (1996) 1.37
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
The p53 tumour suppressor gene. Br J Surg (1998) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene (1991) 1.36
IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene (2000) 1.36
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ (2010) 1.35
C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene (2012) 1.35
p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene (1995) 1.34
p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res (1993) 1.34
Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. Oncogene (1997) 1.34
Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J Biol Chem (1994) 1.33
A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice. Proc Natl Acad Sci U S A (1998) 1.32